The Latest Trading Price of Pfizer Ltd is ₹ 4708 as of 30 Apr 15:30
. The P/E Ratio of Pfizer Ltd changed from 41.6 on March 2021 to 23.9 on March 2025 . This represents a CAGR of -10.49% over 5 yearsThe P/E Ratio of Rekvina Labs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Pfizer Ltd changed from ₹ 20684 crore on March 2021 to ₹ 18317 crore on March 2025 . This represents a CAGR of -2.40% over 5 yearsThe Market Cap of Rekvina Labs Ltd changed from ₹ 2.39 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 years The revenue of Pfizer Ltd for the Dec '25 is ₹ 683.24 crore as compare to the Sep '25 revenue of ₹ 684.19 crore. This represent the decline of -0.14% The revenue of Rekvina Labs Ltd for the Dec '25 is ₹ 0.35 crore as compare to the Sep '25 revenue of ₹ 0.2 crore. This represent the growth of 75% The ebitda of Pfizer Ltd for the Dec '25 is ₹ 208.2 crore as compare to the Sep '25 ebitda of ₹ 271.78 crore. This represent the decline of -23.39% The ebitda of Rekvina Labs Ltd for the Dec '25 is ₹ -0.12 crore as compare to the Sep '25 ebitda of ₹ -0.03 crore. This represent the growth of 300% The net profit of Pfizer Ltd changed from ₹ 150.71 crore to ₹ 141.84 crore over 7 quarters. This represents a CAGR of -3.41%
The net profit of Rekvina Labs Ltd changed from ₹ -0.07 crore to ₹ -0.12 crore over 6 quarters. This represents a CAGR of 43.24%
The Dividend Payout of Pfizer Ltd changed from 32.18 % on March 2021 to 98.34 % on March 2025 . This represents a CAGR of 25.03% over 5 yearsThe Dividend Payout of Rekvina Labs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Pfizer Ltd
Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories.
It has its own manufacturing facility at Goa and Thane.
It has the distinction of being the first pharmaceutical company in India to start clinical research.
The Company sells products in nearly 185 countries having 43 manufacturing sites globally.
About Rekvina Labs Ltd
Rekvina Labs Limited was incorporated on 1st November 1988.
From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of Rs 20 Crore.
It is registered in England and Wales as a Public Limited Company.
The Company is a Quality producer of Pharmaceutical formulations for its customer as per their specific requirements.
It provide contract research and manufacturing services to customers.
The Company is mainly engaged in manufacturing and marketing of pharmaceutical products.
FAQs for the comparison of Pfizer Ltd and Rekvina Labs Ltd
Which company has a larger market capitalization, Pfizer Ltd or Rekvina Labs Ltd?
Market cap of Pfizer Ltd is 21,538 Cr while Market cap of Rekvina Labs Ltd is 26 Cr
What are the key factors driving the stock performance of Pfizer Ltd and Rekvina Labs Ltd?
The stock performance of Pfizer Ltd and Rekvina Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Pfizer Ltd and Rekvina Labs Ltd?
As of May 4, 2026, the Pfizer Ltd stock price is INR ₹4708.15. On the other hand, Rekvina Labs Ltd stock price is INR ₹43.3.
How do dividend payouts of Pfizer Ltd and Rekvina Labs Ltd compare?
To compare the dividend payouts of Pfizer Ltd and Rekvina Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.